Active, not recruitingPhase 2NCT05197426
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Oral Azacitidine(drug)
- Enrollment
- 19 target
- Eligibility
- 55 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- Local Institution - 0011, Huntsville, Alabama, United States
- Local Institution - 0017, Nagoya, Aichi-ken, Japan
- Local Institution - 0023, Nagoya, Aichi-ken, Japan
- Local Institution - 0009, Toyoake, Aichi-ken, Japan
- Local Institution - 0022, Aomori, Aomori, Japan
- Local Institution - 0005, Kamogawa, Chiba, Japan
- Local Institution - 0003, Kashiwa-shi, Chiba, Japan
- Local Institution - 0010, Matsuyama, Ehime, Japan
- Local Institution - 0020, Yoshida Gun, Fukui, Japan
- Local Institution - 0016, Fukuoka, Fukuoka, Japan
- Local Institution - 0014, Ōgaki, Gifu, Japan
- Local Institution - 0001, Maebashi, Gunma, Japan
- Local Institution - 0004, Sapporo, Hokkaido, Japan
- Local Institution - 0019, Kanazawa, Ishikawa-ken, Japan
- Local Institution - 0012, Isehara, Kanagawa, Japan
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05197426 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute